David Baker
Physician Assistant · Fresno, CANPI 1962583740
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $24,086 of the $36,886 with a category attached, or 65.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.0%. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,247 payments — averaging $29.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$5K
- AbbVie$5K
- Pfizer$2K
- Biogen$2K
- UCB, Inc.$2K
- SK Life Science, Inc.$1K
- plus $20K from 54 others
What the payments were for
- Consulting fees$5,31914%
- Speaking & faculty fees$4,25212%
- Travel & lodging$3,0328%
- Food & beverage$24,08665%
- Education$1981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$4,174
- UBRELVY$2,700
- NURTEC ODT$1,650
- DYSPORT$1,418
- AIMOVIG$753
- VYEPTI$507
- GOCOVRI$505
- UPLIZNA$131
- Levorphanol Tartrate$107
How this compares
$36,886 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 102 | $894,139 |
| FinteplaFenfluramine Hcl | 13 | $251,935 |
| XcopriCenobamate | 126 | $194,924 |
| Levorphanol Tartrate | 13 | $127,053 |
| Nurtec OdtRimegepant Sulfate | 73 | $119,726 |
| IngrezzaValbenazine Tosylate | 12 | $94,970 |
| Teriflunomide | 12 | $74,747 |
| Emgality PenGalcanezumab-Gnlm | 99 | $71,057 |
| Aimovig AutoinjectorErenumab-Aooe | 45 | $65,441 |
| RytaryCarbidopa/Levodopa | 99 | $61,781 |
| UbrelvyUbrogepant | 37 | $55,174 |
| BriviactBrivaracetam | 43 | $51,465 |
| FycompaPerampanel | 44 | $42,521 |
| QuliptaAtogepant | 25 | $40,032 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $39,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Nayzilam, Neupro | $1,590 | $359,470108 claims |
| SK Life Science, Inc.Xcopri | $1,462 | $194,924126 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $107 | $127,05313 claims |
| PfizerNurtec Odt | $1,996 | $119,72673 claims |
| AbbVieUbrelvy, Qulipta | $4,565 | $95,20662 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $614 | $94,97012 claims |
| Amneal Pharmaceuticals LLCRytary | $481 | $61,78199 claims |
| Eisai Inc.Fycompa | $5,146 | $42,52144 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $62 | $39,83824 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $75 | $21,41314 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $234 | $9,08013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $501 | $5,91412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Fresno
- Brooke KutkaFresno$67K
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.